Digital Therapeutics & Remote Monitoring for Chronic Diseases in Indonesia
Indonesia’s healthcare system is embracing digital transformation through Digital Therapeutics (DTx) and Remote Patient Monitoring (RPM) — innovative tools that improve chronic disease management, enhance patient engagement, and support preventive, data-driven care across the archipelago. Learn how DTx and RPM are reshaping diabetes, hypertension, and cardiovascular care for millions.
10/29/20252 min read
INAVIMED, October 2025 — Indonesia faces a growing chronic disease burden — cardiovascular disease, diabetes, and hypertension are leading causes of disability and death. Digital therapeutics (DTx) and remote patient monitoring (RPM) offer practical ways to improve long-term disease management, expand access in remote areas, and support Indonesia’s move toward preventive, data-driven care.
What are DTx and RPM?
Digital therapeutics are evidence-based software interventions that prevent, manage, or treat medical conditions (for example, mobile apps that deliver behavior change programs for diabetes). Remote monitoring uses connected devices (blood glucose meters, BP cuffs, wearables) to send clinical data to providers for ongoing care and timely intervention. Together they enable continuous care outside the clinic.
Why Indonesia is ripe for digital solutions
The COVID-19 pandemic accelerated telehealth adoption across Indonesia and exposed the value of remote care. The government’s digital health strategy envisions integrated national health data platforms (IHS) and a stronger digital health ecosystem — aiming to reduce fragmentation and improve service delivery across islands and rural regions.
Evidence of Impact
Systematic reviews show DTx and RPM can improve disease self-management, glycemic control in diabetes, blood pressure management, and medication adherence when combined with clinical oversight. These interventions can reduce hospital visits and support earlier detection of deterioration. However, effectiveness depends on clinical integration, user engagement, and data quality.
Opportunities and Recommendations
Pilot evidence-based DTx for high-burden conditions (diabetes, hypertension) with robust evaluation and local adaptation.
Strengthen regulation and data governance to protect patient data and standardize clinical quality.
Invest in connectivity and training for primary care teams in remote areas; leverage national screening programs to link patients to digital services.
Foster public–private partnerships to scale proven RPM models while ensuring affordability and equity.
DTx and RPM have strong potential to transform chronic disease care in Indonesia, but success depends on evidence-backed programs, clear regulation, infrastructure investment, and deliberate efforts to reach underserved populations. With coordinated policy and careful implementation, digital tools can strengthen prevention, monitoring, and long-term outcomes for millions of Indonesians.
Keywords:
Digital therapeutics (DTx), Remote patient monitoring (RPM), Chronic disease management, Indonesia healthcare, Digital health transformation, Diabetes management, Cardiovascular disease prevention, Telemedicine in Indonesia, Health technology innovation, Personalized medicine, Preventive healthcare, Mobile health apps
Source:
Pradipta IS, Aprilio K, Ningsih YF, Pratama MAA, Alfian SD, Abdulah R. How does Indonesian chronic disease patient adhere to their treatment? Patient Prefer Adherence. 2025;19:173-84.
World Health Organization. Global strategy on digital health 2020–2025. Geneva: WHO; 2021.
Li M, Brown J, Nguyen T, et al. Impact of digital therapeutics on the management of chronic diseases: systematic review. J Med Internet Res. 2025;27:e54321.
